Ipsen | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
153,100.00
154,000.00
190,800.00
226,500.00
272,900.00
389,100
Depreciation, Depletion & Amortization
41,800.00
43,900.00
47,000.00
49,600.00
97,900.00
126,400
Other Funds
5,700.00
600.00
300.00
3,000.00
500.00
39,100
Funds from Operations
209,200.00
240,500.00
304,800.00
318,700.00
444,100.00
573,800
Changes in Working Capital
21,100.00
5,300.00
81,100.00
900.00
21,200.00
2,900
Net Operating Cash Flow
188,100.00
245,800.00
223,700.00
317,800.00
422,900.00
570,900
Capital Expenditures
62,400.00
84,400.00
75,200.00
372,300.00
240,800.00
Sale of Fixed Assets & Businesses
200.00
300.00
200.00
3,600.00
400.00
Purchase/Sale of Investments
300.00
300.00
-
1,000.00
1,600.00
Net Investing Cash Flow
103,700.00
93,700.00
106,200.00
357,100.00
777,200.00
Cash Dividends Paid - Total
66,600.00
65,500.00
70,000.00
70,000.00
70,200.00
Issuance/Reduction of Debt, Net
100.00
3,000.00
4,500.00
324,000.00
216,500.00
Net Financing Cash Flow
76,600.00
97,700.00
91,200.00
252,000.00
135,200.00
Net Change in Cash
12,100.00
54,700.00
33,900.00
208,500.00
213,200.00
Free Cash Flow
146,100.00
198,400.00
173,700.00
236,600.00
338,000.00
Deferred Taxes & Investment Tax Credit
8,200.00
13,800.00
1,400.00
8,100.00
48,300.00
19,200
Net Assets from Acquisitions
-
100.00
31,400.00
-
549,500.00
Other Sources
-
-
8,000.00
14,000.00
20,500.00
Change in Capital Stock
15,600.00
28,600.00
17,000.00
5,000.00
10,600.00
Exchange Rate Effect
4,300.00
300.00
7,600.00
4,200.00
5,900.00
Other Uses
41,800.00
9,800.00
7,800.00
1,400.00
6,200.00

About Ipsen

View Profile
Address
65, quai Georges Gorse
Boulogne-Billancourt Ile-de-France 92650
France
Employees -
Website http://www.ipsen.com
Updated 07/08/2019
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin.